Bio & Pharma
GC Biopharma, Sanofi to jointly market Plavix
GC will be responsible for the sales and marketing of the anti-platelet drug Plavix in S.Korea
By Feb 13, 2023 (Gmt+09:00)
1
Min read
Most Read
Macquarie Korea Asset Management confirms two nominees
Deutsche Bank's Korea IB head quits after country head resigns
S.Korea's LS Materials set to boost earnings ahead of IPO process
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Netmarble sells stake in BTS label HYBE stake for $161 mn
GC Biopharma Co. (formerly Green Cross Corp.) said on Monday it has entered into a joint sales partnership with Sanofi-Aventis Korea, the South Korean subsidiary of multinational pharmaceuticals company Sanofi, for Plavix 75 mg, an antiplatelet medication.
The agreement calls for GC Biopharma to take charge of the sales and marketing of Plavix, focusing primarily on domestic clinics.
Plavix is an antiplatelet drug prescribed for patients who have suffered a stroke, myocardial infarction or peripheral arterial disease.
"We are committed to continuing our cooperation with initiatives such as open innovation and joint sales partnerships to provide various treatment options for managing the risk factors of chronic diseases in Korea," said an official from GC Biopharma.
Write to Jung-Eun Kim at likesmile@hankyung.com
More to Read
-
Bio & PharmaGC Biopharma confirms safety of flu vaccine in phase 1 trial
Dec 15, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaGC Biopharma's Sanfilippo treatment eligible for FDA priority review
Jan 18, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaGC Biopharma's Ochang facility gets WHO PQ certification
Feb 10, 2023 (Gmt+09:00)
1 Min read -
COVID-19Green Cross in talks with Russia to produce COVID-19 vaccine
Mar 18, 2021 (Gmt+09:00)
3 Min read
Comment 0
LOG IN